Pepscan Therapeutics Signs Multi-Target Agreement for Antibody Discovery
LELYSTAD, the Netherlands, January 7, 2013 /PRNewswire/ –
Pepscan Therapeutics, a world leader in protein mimicry technologies for raising
anti-GPCR antibodies, today announced a multi-target research agreement with an
undisclosed US-based antibody discovery company. Under the agreement Pepscan using its
CLIPS platform and other protein mimicry technologies will work with the partner in the
discovery of novel antibodies. Under the terms of the agreement, Pepscan will receive R&D
funding and could receive payments on the achievement of research and clinical milestones,
as well as royalties on sales of products resulting from the collaboration. Financial
details of the agreement were not disclosed.
“We are excited to collaborate in this partnership, since we strongly believe that
Pepscan’s peptide design and protein mimicry technology combined with our partner’s
world-class platform for antibody discovery and optimization will yield truly innovative
therapeutic products,” said Wim Mol, CEO of Pepscan. “We recognize the perfect match of
our combined technologies – Pepscan designing and providing tailored peptide immunogens,
and our partner applying its state-of-the-art antibody discovery platform. We therefore
believe that this agreement only forms the start of a promising and productive
relationship between our two companies.”
About Pepscan: Pepscan Therapeutics B.V. is a privately held company based in
Lelystad, The Netherlands. Pepscan is using its proprietary CLIPS protein mimicking
technology for the development of novel constrained therapeutic peptides and immunogens.
Besides its pipeline of proprietary anti-GPCR monoclonal antibody products, Pepscan has
various ongoing collaborations with leading pharmaceutical and biotech companies to
develop novel therapeutics based on the proprietary CLIPS technology.
About CLIPS: CLIPS (Chemical LInkage of Peptides onto Scaffolds) is a technology to
present one or more peptides in a structurally constrained configuration. These molecules
behave as functional mimics of structurally complex protein domains. CLIPS therapeutic
peptides have been shown to exert excellent activity and stability. CLIPS peptides are
also used as superior immunogens for antibody generation against disease relevant protein
targets. This is especially valuable in the case of proteins that are inaccessible as
recombinant proteins, such as GPCRs.
SOURCE Pepscan Therapeutics